Spinogenix Announces Full Enrollment in its Phase 2 Trial Evaluating SPG302 as a First-in-Class Synaptic Regenerative Therapy for Alzheimer's Disease

First Cohort Results to be Presented at AAIC in Toronto, July 2025 FDA Clears IND in Alzheimer’s Disease, Enabling Future Expansion to U.S. LOS ANGELES, June 24, 2025 /PRNewswire/ — Spinogenix, Inc. , a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced full enrollment of its Phase 2 clinical trial in Australia evaluating SPG302 for the treatment of people with Alzheimer’s disease (AD). SPG302 is a once-daily pill with the potential to regenerate synapses and reverse cognitive decline in people with mild to moderate AD.

The release as fetched from its publisher. spinogenix.com ↗